Studied by 2 people
Looks like no one added any tags here yet for you.
Registration, medical history and physical examination
Aseptic technique, scrub site for minimum 30 seconds - providine-iodine scrub
90-180 mmHg Systolic
50-100 mmHg Diastolic or Medical Director exception
Possible exposure to malaria
Asymptomatic during the time
Visitor/immigrant from area endemic for malaria
Previously diagnosed with malaria
Definite disease or habits strongly associated with bloodborne pathogens
Viral diseases:
Viral hepatitis after age 11
Confirmed positive test for HBsAg or positive HBV NAT result
Repeatedly reactive test for anti-HBc or anti-HTLV
Donated only unit to recipient who developed post transfusion hepatitis, HIV or HTLV
Present/Past infection of HCV, HTLV, HIV or T. cruzi
Evidence of parenteral drug use
Other Diseases:
Family history of CJD or risk of vCJD
History of babesiosis
Donations for self; no age limit
Hct ≥ 33%; Hgb ≥ 11 g/dL
No bacteremia
Collection > 72 hours prior to surgery or transfusion
Use regular blood bags; volume drawn < 10.5 mL/kg body weight for minimum weight (450 + 45 mL plus testing samples)
If 300-404 mL drawn, label as “Red Blood Cells Low Volume” (other components may not be made from these units)
Donor criteria same as for whole blood
Limits number of donor exposures
Apheresis instruments can selectively remove needed component(s) and return components not needed
Donations at least 2 days apart and no more than 2 in any 7 day period
If RBCs collected and cannot be returned, must wait 8 weeks
Used to reconstitute bone marrow post chemotherapy/irradiation or to replace abnormal marrow cells with normal marrow cells (congenital immune deficiencies, anemias, malignant disorders of bone marrow, red cell disorders, etc.)
Cells obtained from bone marrow, umbilical cord blood and peripheral blood (apheresis)
Clinically significant antibodies
FFP cannot be prepared from these units; platelets and cryoprecipitate can (contain minimum plasma volume)
HBsAg
Anti-HBc
Anti-HCV
Anti-HIV 1/2
Anti-HTLV I/II
NAT Testing for:
HIV 1- RNA
HCV RNA
West Nile RNA
HBV DNA
Zika RNA
Red cells with plasma removed
Provides same oxygen carrying capacity as whole blood with less volume
< 80% Hct (indicates sufficient plasma removal); 55-65% Hct if additive solution used
1 unit raises hemoglobin (Hgb) 1 g/dL or hematocrit (Hct) 3%
Changes in plasma during storage (1-6 C)
INCREASED: NH4 and K+
DECREASED: pH and Na+
Unit of blood cannot be returned and reissued if > 10C or if seal disturbed
Plasma removed by successive saline washes (automated instrument)
Primarily used to prevent allergic response to plasma proteins and anaphylactic shock in IgA-deficient patients with anti-IgA (IgA is in normal plasma); removes anti-HPA-1a from maternal blood used to neonatal transfusions; removes complement
Expires 24 hours after seal of original unit broken
Hemoglobin should be ≥ 60 g in individual units or > 50 g in 95% of units tested
Leukoreduced - < 5x10^6 leukocytes / unit with final hgb of ≥ 51g in individual units or > 42.5 g in 95% of units tested
85% of red cells retained
Final WBC count < 5 x 10^6 to prevent febrile nonhemolytic reactions, HLA alloimmunization, and the transmission of CMV
Preparation by filtration during processing or at bedside
Used primarily for patients with repeated febrile nonhemolytic (FNH) reactions; usually due to presence of cytokines released from white cells or alloimmunization to HLA or leukocyte antigens
Cells protected from ultra low temperatures by cryoprotective agent (40% glycerol)
Used for storage of autologous units and “rare” units; expires in 10 years
Must be thawed at 37C, glycerol removed prior to transfusion, and ≥ 80% RBC recovery
Stored at ≤ - 65C; 1-6C for 24 hours after deglycerolizing (open system)
Prepared by separating cells and plasma by centrifugation and freezing plasma within 8 hours of collection
Expires 1 year from date of collection when stored at ≤ -18C or 7 years stored at ≤ -65C
Once thawed (between 30-37C), expires in 24 hours, if stored at 1-6C
Must be ABO compatible with recipient cells; not necessarily ABO identical
Used for multiple coagulation deficiencies, Factor XI deficiency, and other congenital deficiencies for which no concentrate is available
Collection is from males or never pregnant females to prevent TRALI
Plasma frozen to ≤ -18C within 24 hours of collection from whole blood or apheresis
Apheresis plasma kept at 1-6C for 24 hours and then frozen at ≤ -18C
When FFP frozen within 8 hours of whole blood collection is thawed at 1-6C, a cold insoluble portion of plasma forms - CRYO
CRYO is separated from thawed FFP and refrozen within one hour
Must contain ≥ 150 mg of fibrinogen and ≥ 80 IU/bag of Factor VIII
Also contains vWF, ristocetin cofactor activity, Factor XIII and fibronectin
Store at ≤ -18C for 1 year from date of phlebotomy; room temperature after thawing
Transfuse within 6 hours of thawing; 4 hours after pooling in an open system; 6 hours after pooling in a closed system
Most commonly used to replace fibrinogen loss due to DIC and/or massive bleeding or for dysfibrinogenemia with active bleeding
pH ≥ 6.2 at end of storage; stored in volume of plasma necessary to maintain pH, usually 40-70 mL for whole blood derived platelets
≥ 5.5 x 10^10 platelets/unit in 75% of units tested or ≥ 3 x 10^11 platelets/plateletpheresis in 90% of units tested
Stored with continuous gentle agitation at 20-24C (room temp)
Outdate is 5 days
Must have method to detect and limit bacterial contamination
May have some residual RBCs; consider administering RhIg to RhD neg women of childbearing age who have received D pos platelets
Obtained by apheresis
Granulocyte colony-stimulating factor (G-CSF) increases yield
Used for neutropenic patients with documented gram negative sepsis who have not responded to antibiotics
Can transmit CMV, induce HLA immunization, and cause GVHD, if not irradiated
Stored without agitation at 20-24C for up to 24 hours, but should be transfused ASAP
Should be ABO-compatible with recipient; crossmatch if >2mL RBCs
Prevents graft (donor lymphs) and vs. host disease (GVHD) (inactivates T cells)
For anyone at GVHD risk: fetus receiving intrauterine transfusion; donor is blood relative of recipient; donor is HLA matched; or congenital immunodeficiency
Minimum of 25 Gy (gray) or 2500 cGy (centigray) delivered to center of container; minimum dose of 15Gy to any point
RBCs expired on original outdate or 28 days after irradiation, whichever is first
Red cells kept at 1-10C
Platelets and granulocytes kept at 20-24C
Frozen components kept frozen
Products stored at 1-6C = 24 hours
Products stored at 20-24C = 4 hours
If red cells visible in pooled product, patient plasma antibodies should be compatible with those red cells
Expiration of pooled components
Platelets - 4 hours (open system)
Cryoprecipitate - 4 hours (open system); 6 hours (closed system)
1-6°C (closed system)
21 days (ACD, CPD, CP2D)
35 days (CPDA-1)
42 days (Additive)
1-6°C (open system), 24 hours
1-6°C
CPDA-1: 35 days
Additive system: 42 days
Open system: 24 hours
1-6°C
CPDA-1: 35 days
Additive system: 42 days
Open system: 24 hours
≥ 80% of Original Red Cells
Adequate Removal of Cryoprotective Agent (glycerol)
10 years, -65°C or Colder (40% Glycerol)
-120°C (20% Glycerol)
24 hours once deglycerolized (open system)
Frozen to ≤ -18°C within 8 hours
Frozen to ≤ -18°C within 24 hours
12 months, ≤ -18°C
7 years ≤ -65°C or Colder
≥ 5.5 x 10^10 Platelets in 75% of Units Tested
< 8.3 x 10^5 Leukocytes in 95% of Units Tested
< 5 x 10^6 in Pooled Platelets
≥ 3.0 x 10^11 plt/unit in 90% of Units Tested
pH 6.2 or Greater at Maximum Storage Time, < 5 x 10^6 leukocytes in 95% units tested
5 days, 20-24°C with Constant Agitation
24 Hours (Open System)
Principal subgroups of A
Serological difference based on reactivity with anti-A1 (Dolichos biflorus* or human anti-A1). (*lectin - plant or seed extract diluted to agglutinate specific human blood group antigens)
A1 cells are agglutinated
A2 cells are NOT agglutinated
